Table 1 Baseline characteristics of RP+CME group, RP-CME group and all patients

Age (mean ± SD, range)

47.12 ± 14.26, 17–76

44.65 ± 13.58, 24–75

47.94 ± 14.39, 17–76

t = 0.953, p = 0.343

Gender

Male = 48 (52.17%)

Female = 44 (47.83%)

Male = 14 (60.87%)

Female = 9 (39.13%)

Male = 34 (49.28%)

Female = 35 (50.72%)

𝞦²=0.929, p = 0.335

Better-seeing eye BCVA, ETDRS letters (median, IQR)

71 (65–81)

73 (65–85)

70 (65–80)

Z=-1.100, p = 0.271

EZA, median, (IQR) mm²

0.802

(0.0674-3.010)

1.724 (0.550–4.051)

1.096 (0.209–4.043)

Z=-1.136, p = 0.254

Causal gene mutation, n

EYS = 46

RPGR = 13

CNGB1 = 4

RHO = 4

CEP290 = 2

RPE65 = 2

USH2A = 2

IMPG1 = 2

PRPF31 = 2

SLC66A1 = 1

HGSNAT = 1

PDE6B = 1

GRK1 = 1

ARL2BP = 1

AGBL5 = 1

NR2E3 = 1

PRPF8 = 1

Inconclusive = 7

EYS = 9

RHO = 2

RPGR = 1

SLC66A1 = 1

USH2A = 1

CNGB1 = 1

HGSNAT = 1

IMPG1 = 1

PDE6B = 1

PRPF31 = 1

Inconclusive = 4

EYS = 37

RPGR = 12

CNGB1 = 3

CEP290 = 2

RPE65 = 2

RHO = 2

USH2A = 1

IMPG1 = 1

PRPF31 = 1

GRK1 = 1

ARL2BP = 1

AGBL5 = 1

NR2E3 = 1

PRPF8 = 1

Inconclusive = 3

NA